Hausburg Frauke, Jung Julia Jeannine, David Robert
Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), Department of Cardiac Surgery, Rostock University Medical Center, Schillingallee 69, 18057, Rostock, Germany.
Department Life, Light and Matter of the Interdisciplinary Faculty at Rostock University, Albert-Einstein-Strasse 25, 18059, Rostock, Germany.
Adv Biochem Eng Biotechnol. 2018;163:71-115. doi: 10.1007/10_2017_27.
Many disorders are manifested by dysfunction of key cell types or their disturbed integration in complex organs. Thereby, adult organ systems often bear restricted self-renewal potential and are incapable of achieving functional regeneration. This underlies the need for novel strategies in the field of cell (re-)programming-based regenerative medicine as well as for drug development in vitro. The regenerative field has been hampered by restricted availability of adult stem cells and the potentially hazardous features of pluripotent embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Moreover, ethical concerns and legal restrictions regarding the generation and use of ESCs still exist. The establishment of direct reprogramming protocols for various therapeutically valuable somatic cell types has overcome some of these limitations. Meanwhile, new perspectives for safe and efficient generation of different specified somatic cell types have emerged from numerous approaches relying on exogenous expression of lineage-specific transcription factors, coding and noncoding RNAs, and chemical compounds.It should be of highest priority to develop protocols for the production of mature and physiologically functional cells with properties ideally matching those of their endogenous counterparts. Their availability can bring together basic research, drug screening, safety testing, and ultimately clinical trials. Here, we highlight the remarkable successes in cellular (re-)programming, which have greatly advanced the field of regenerative medicine in recent years. In particular, we review recent progress on the generation of cardiomyocyte subtypes, with a focus on cardiac pacemaker cells. Graphical Abstract.
许多疾病表现为关键细胞类型功能障碍或它们在复杂器官中整合紊乱。因此,成体器官系统通常自我更新潜力有限,无法实现功能再生。这构成了基于细胞(重)编程的再生医学领域新策略以及体外药物开发需求的基础。再生领域受到成体干细胞可用性受限以及多能胚胎干细胞(ESC)和诱导多能干细胞(iPSC)潜在有害特征的阻碍。此外,关于ESC产生和使用的伦理问题和法律限制仍然存在。针对各种具有治疗价值的体细胞类型建立直接重编程方案克服了其中一些限制。同时,依靠谱系特异性转录因子、编码和非编码RNA以及化合物的外源表达的众多方法为安全高效地产生不同特定体细胞类型带来了新的前景。开发生产具有与内源性对应细胞理想匹配特性的成熟且生理功能正常的细胞的方案应是最优先事项。这些细胞的可用性可将基础研究、药物筛选、安全性测试以及最终的临床试验结合起来。在此,我们强调细胞(重)编程方面取得的显著成功,这些成功近年来极大地推动了再生医学领域的发展。特别是,我们综述了心肌细胞亚型产生方面的最新进展,重点是心脏起搏器细胞。图形摘要。